IR@PKUHSC  > 北京大学药学院
学科主题药学
In vitro and in vivo antitumor activity of oridonin nanosuspension
Lou, Haiyan2; Zhang, Xiumei2; Gao, Lei3; Feng, Feifei1; Wang, Juying2; Wei, Xinbing2; Yu, Zongqin1; Zhang, Dianrui1; Zhang, Qiang4
关键词Oridonin Nanosuspension Antitumor Cytotoxicity
刊名INTERNATIONAL JOURNAL OF PHARMACEUTICS
2009-09-08
DOI10.1016/j.ijpharm.2009.06.022
379期:1页:181-186
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
资助者National Nature Science Foundation of China ; National Basic Research Program of China ; National Nature Science Foundation of China ; National Basic Research Program of China
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]PARTICLE-SIZE REDUCTION ; POORLY SOLUBLE DRUGS ; CANCER-THERAPY ; NANOPARTICLES ; DELIVERY ; FORMULATION ; CELLS ; APOPTOSIS ; SYSTEMS
英文摘要

The aim of the present study was to evaluate the antitumor activity of an oridonin (ORI) nanosuspension relative to ORI solution both in vitro and in vivo. ORI nanosuspension with a particle size of 897.2 +/- 14.2 nm was prepared by the high pressure homogenization method (HPH). MTT assay showed that ORI nanosuspension could significantly enhance the in vitro cytotoxicity against K562 cells compared to the ORI solution, the IC(50) value at 36 h was reduced from 12.85 mu mol/L for ORI solution to 8.11 mu mol/L for ORI nanosuspension. Flow cytometric analysis demonstrated that the ORI nanosuspension also induced a higher apoptotic rate in K562 cells compared to ORI solution. In vivo studies in a mouse model of sarcoma-180 solid tumors demonstrated significantly greater inhibition of tumor growth following treatment with ORI nanosuspension than ORI solution at the same dosage. The mice injected with ORI nanosuspension showed a higher reduction in tumor volume and tumor weight at the dose of 20 mg/kg compared to the ORI solution (P<0.01), with the tumor inhibition rate increased from 42.49% for ORI solution to 60.23% for the ORI nanosuspension. Taken together, these results suggest that the delivery of ORI in nanosuspension is a promising approach for the treatment of the tumor. (C) 2009 Elsevier B.V. All rights reserved.

语种英语
所属项目编号30672674 ; 2009CB930300
资助者National Nature Science Foundation of China ; National Basic Research Program of China ; National Nature Science Foundation of China ; National Basic Research Program of China
WOS记录号WOS:000269809600023
Citation statistics
Cited Times:42[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61059
Collection北京大学药学院
作者单位1.Shandong Univ, Sch Pharm, Dept Pharmaceut, Jinan 250012, Shandong Prov, Peoples R China
2.Shandong Univ, Sch Pharm, Dept Pharmacol, Jinan 250012, Peoples R China
3.First Affiliated Hosp Gen Hosp PLA, Dept Pharm, Beijing 100037, Peoples R China
4.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China
Recommended Citation
GB/T 7714
Lou, Haiyan,Zhang, Xiumei,Gao, Lei,et al. In vitro and in vivo antitumor activity of oridonin nanosuspension[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2009,379(1):181-186.
APA Lou, Haiyan.,Zhang, Xiumei.,Gao, Lei.,Feng, Feifei.,Wang, Juying.,...&Zhang, Qiang.(2009).In vitro and in vivo antitumor activity of oridonin nanosuspension.INTERNATIONAL JOURNAL OF PHARMACEUTICS,379(1),181-186.
MLA Lou, Haiyan,et al."In vitro and in vivo antitumor activity of oridonin nanosuspension".INTERNATIONAL JOURNAL OF PHARMACEUTICS 379.1(2009):181-186.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Lou, Haiyan]'s Articles
[Zhang, Xiumei]'s Articles
[Gao, Lei]'s Articles
百度学术
百度学术Similar articles in
[Lou, Haiyan]'s Articles
[Zhang, Xiumei]'s Articles
[Gao, Lei]'s Articles
必应学术
必应学术Similar articles in
[Lou, Haiyan]'s Articles
[Zhang, Xiumei]'s Articles
[Gao, Lei]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.